Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban versus warfarin for stroke and systemic embolism prevention in non-valvular atrial fibrillation
ACTRN12607000214437Phase 3Completed
- Sponsor
- Bayer
- Start
- Dec 2006
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, double-blind trial in Atrial fibrillation (AFib), stroke and systemic embolism comparing Rivaroxaban arm with Warfarin arm (2 arms). Primary endpoint: Primary efficacy outcome. Started Dec 2006; status: completed.
02
Drugs
rivaroxabanwarfarin
03
Conditions
Atrial fibrillation (AFib)strokesystemic embolism
Beyond the preview
Go deeper on ACTRN12607000214437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12607000214437.